Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Events next week:
The pipeline of IPOs just kept swelling as seen above. But this week has been all about the resurgence of Australia IPOs with the launch/pending launch of GQG Partners (1402558D US), Judo Bank (1628888D AU), and Vulcan Steel (VSL AU) bookbuilds. There is also SiteMinder, SG Lottery (SGL AU), and Ventia (CIMIC spin-off) looking to launch soon as well.
This week in Hong Kong, Clover Biopharmaceuticals (CBL HK) joined the long list of IPOs approved and pending bookbuild launch. We also initiated on Biocytogen Pharmaceuticals (Beijing) (BCP HK), a pre-clinical and clinical stage research service biopharma company, looking to raise up to US$300m.
But recent Hong Kong biotech IPO performance hasn't been great as seen from Abbisko Cayman (2256 HK)'s disappointing performance this week.
Large Japan placements, Hulic Co Ltd (3003 JP) and SUMCO Corp (3436 JP) have traded well post-pricing which should bolster sentiment for Japan Post Holdings (6178 JP)'s bookbuild which is ongoing until 22nd October and pricing will be on 25th October.
However, PHC Holdings (6523 JP)'s IPO did not trade well even after downsizing the IPO and pricing it at the low end.
In India, FSN E-Commerce Ventures (Nykaa) (1003622D IN) is looking to launch its IPO later this month. More IPOs should come soon too as it was reported that Adani Wilmar and Star Health Insurance IPOs have secured their approval from SEBI this week.
In Korea, Kakao Pay (377300 KS) will open its books on this coming Wednesday, for a day. We took a look at valuation again and also compared it to KakaoBank (323410 KS).
Last, but not least, tearsheets for newly filed IPOs this week:
Our overall accuracy rate is 73.6% for IPOs and 67.9% for Placements
(Performance measurement criteria is explained at the end of the note)
Hong Kong/China
US/China ADR
India
Japan/Korea
Others
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.